The field of multiple myeloma has transformed from having few treatments to an abundance of effective drugs. The primary clinical challenge is no longer finding a therapy that works, but rather determining the optimal sequence and combination of available options, highlighting a unique form of market maturity.

The powerful Tec-Dara combination therapy initially showed a paradoxical drop in overall survival due to infections. Mandating IVIG prophylaxis completely negated this early risk, revealing the treatment's true, significant long-term survival advantage. This highlights that aggressive supportive care is critical for maximizing efficacy.

The DREAM-7 trial showed a belantumab combination had an overall survival benefit versus a daratumumab regimen, a "premier drug" that previously changed the myeloma treatment landscape. This surprising result establishes a new, higher standard of care and positions belantumab as a top-tier therapy, not merely another option.

The Determination II trial chose isatuximab over daratumumab for its induction regimen based on two factors. First, it may have an edge in high-risk myeloma (1q amplified). Second, its less frequent dosing schedule (weekly for one month) reduces the myelosuppression seen when combining iberdomide with daratumumab.

The effectiveness of modern daratumab-based therapies has significantly improved patient outcomes. This positive development paradoxically made previous staging systems, founded in eras with less effective treatments, unable to accurately identify the highest-risk patients, necessitating the creation of a new prognostic model for the current era.

Five-year follow-up from the CARTITUDE-1 trial suggests a potential cure for multiple myeloma is achievable. With roughly one-third of heavily pretreated patients remaining in remission at five years—and some confirmed as MRD-negative—the concept of a cure is now part of the operational discussion among specialists, a monumental shift for a disease long considered incurable.

Based on findings from the DETERMINATION-1 and MIDAS trials, which questioned the overall survival benefit of early transplant, new strategies are emerging. The DETERMINATION-2 trial will use iberdomide-based therapy and defer transplant for standard-risk, MRD-negative patients, reserving it for higher-risk cases.

CARTITUDE-IV trial data challenges the idea of reserving CAR-T therapy for high-risk myeloma. In early relapse, standard-risk patients treated with siltacel had a longer progression-free survival than even high-risk patients on the same therapy. This suggests standard-risk patients may gain the most relative benefit from earlier CAR-T intervention compared to standard of care.

The Serena 6 trial pioneers a shift from reacting to visible tumor growth to proactively treating molecular signals. By intervening upon detection of an ESR1 mutation—before radiographic progression—the study suggests this approach can improve quality of life and delay disease advancement, challenging the current standard of care.